• Wondering whether Revvity at about US$96.95 is offering fair value or a potential mispricing opportunity? This article walks through the key signals to help you frame that question clearly.
• The stock has recently gained 3.2% over the last 7 days and 11.7% over the last 30 days, even though it is still down 1.2% year to date. Its 3 year and 5 year returns of 16.2% and 32.4% respectively are also in decline.
• Recent coverage has focused on Revvity’s position within life sciences and diagnostics, as investors reassess how the business fits into broader healthcare trends. That context matters because changing expectations about the company’s role and prospects often shape how much investors are willing to pay for the stock.
• Right now, Revvity has a value score of 2 out of 6. The rest of this article will break down how different valuation methods line up with that score, before finishing with a way to look at valuation that can give you an even richer picture of the stock.

Revvity scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Revvity Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes the cash the company is expected to generate in the future and discounts those projections back to today to estimate what the business might be worth right now.

For Revvity, the DCF uses a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month Free Cash Flow is about $486.9 million. Analyst estimates and extrapolations point to Free Cash Flow of $781 million in 2029, with a series of projected annual cash flows between 2026 and 2035 that are discounted back to today in the model.

Pulling those discounted cash flows together, the DCF model arrives at an estimated intrinsic value of $137.70 per share. Compared with the recent share price of about $96.95, this implies the stock is 29.6% undervalued according to this method.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Revvity is undervalued by 29.6%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.

Approach 2: Revvity Price vs Earnings

For a profitable company like Revvity, the P/E ratio is a useful shorthand because it links what you pay for the stock directly to the earnings it generates. Investors usually accept a higher P/E when they expect stronger earnings growth or see lower risk, and a lower P/E when they expect slower growth or see higher risk.

Revvity currently trades on a P/E of 45.23x. That sits above the Life Sciences industry average of 34.22x and also above the peer average of 36.88x. On those simple comparisons, the stock looks relatively expensive.

Simply Wall St’s Fair Ratio offers another lens. It estimates what a more tailored P/E might look like, at 20.94x for Revvity, based on factors such as earnings growth, profit margins, industry, market cap and company specific risks. Because it adjusts for these characteristics, the Fair Ratio can be more informative than a basic peer or industry comparison.

Comparing Revvity’s current P/E of 45.23x with the Fair Ratio of 20.94x suggests the stock is trading well above that tailored benchmark.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Revvity Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives take the next step by letting you attach a clear story about Revvity to the numbers you believe in, connecting your assumptions about future revenue, earnings and margins to a Fair Value that you can compare with today’s price.

On Simply Wall St’s Community page, Narratives are an accessible tool used by millions of investors. You can see how different views, such as a more cautious fair value of US$95.00 or a more optimistic fair value of US$140.00 for Revvity, are each tied to specific forecasts like revenue growth in the 5.3% to 6.4% range, profit margins between about 19.9% and 20.9%, future P/E multiples from 16.6x to 24.9x and a discount rate around 8.6%.

Because each Narrative links a company story to a forecast and then to a Fair Value, it helps you decide whether Revvity looks more attractive or less attractive by comparing that Fair Value with the current share price. Narratives are kept current as new earnings, guidance, news and analyst targets come in so your decision making stays aligned with the latest information.

For Revvity, however, we will make it really easy for you with previews of two leading Revvity Narratives:

Fair value in this bullish Narrative: US$140.00 per share

Implied discount to that fair value at about US$96.95: roughly 30.8% undervalued

Revenue growth assumption used: 6.36% a year

• Leans into Revvity's role in genomics and diagnostic automation, with newborn whole genome sequencing and lab workflow upgrades seen as key drivers for higher revenue and margins over time.
• Highlights software ARR, 115% net retention and a rapid move to SaaS as reasons to expect a larger share of recurring, higher margin revenue.
• Acknowledges risks from regulation, funding pressure and product differentiation, but frames them as hurdles that could be outweighed if execution on automation, software and targeted M&A continues to support growth and margins.

Fair value in this cautious Narrative: US$95.00 per share

Implied premium to that fair value at about US$96.95: roughly 2.1% overvalued

Revenue growth assumption used: 5.34% a year

• Focuses on regulatory shifts such as DRG related changes in China and wider reimbursement pressure that could weigh on diagnostics revenue and margins.
• Emphasizes Revvity's exposure to biopharma and diagnostics budgets, where weaker funding, cost controls and softer capital equipment demand could restrain growth and earnings.
• Flags ongoing cost pressures, FX, tariffs and healthcare cost containment as reasons why margin improvements and higher earnings might be harder to achieve than more optimistic forecasts suggest.

If you want to see how these narratives, and others from the community, tie into your own assumptions about Revvity, you can compare them side by side and decide which fair value story feels closer to the way you see the stock.

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Revvity on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Do you think there's more to the story for Revvity? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.